Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- CRBP -2.8%, JP -2.6%, VRAY -1.7%
Other news:
- OREX -69.3% (plans for near-term sale using structured process through Chapter 11 Of U.S. Bankruptcy Code)
- SVRA -16.2% (fails to meet primary endpoint in the indie Phase 2 clinical study conducted by the heart failure clinical research network)
- ESPR -7.7% (following news from SNY and REGN to make Praluent more accessible and affordable for patients)
- BGCP -1% (entered into Controlled Equity Offering for up to $300 mln of shares of class A common stock)
Analyst comments:
- BK -0.7% (downgraded to Neutral from Buy at Goldman)
- RHT -0.8% (downgraded to Neutral at Mizuho)
- NEM -1.1% (downgraded to Underperform from Sector Perform at RBC Capital Mkts)
- HUBS -1.4% (downgraded to In-line from Outperform at Evercore ISI)